



DOI: 10.4274/jcrpe.galenos.2025.2025-3-29  
J Clin Res Pediatr Endocrinol 2026;18(1):1-10

# Diabetic Peripheral Neuropathy in Children and Adolescents - Prevalence, Diagnostic Methods and Risk Factors

✉ Marta Baszyńska-Wilk<sup>1</sup>, ✉ Monika Nowacka-Gotowiec<sup>2</sup>, ✉ Elżbieta Moszczyńska<sup>1</sup>

<sup>1</sup>The Children's Memorial Health Institute, Department of Endocrinology and Diabetology, Warsaw, Poland

<sup>2</sup>The Children's Memorial Health Institute, Electromyography and Evoked Potential Laboratory, Warsaw, Poland

**Cite this article as:** Baszyńska-Wilk M, Nowacka-Gotowiec M, Moszczyńska E. Diabetic peripheral neuropathy in children and adolescents - prevalence, diagnostic methods and risk factors. J Clin Res Pediatr Endocrinol. 2026;18(1):1-10

## ABSTRACT

Diabetic peripheral neuropathy (DPN) is the most common form of acquired neuropathy. In children with type 1 diabetes, the reported prevalence of DPN varies widely, ranging from 3% to 62%, mainly due to differences in screening methodologies and patient population characteristics. While intraepidermal nerve fiber density assessment via skin biopsy remains the gold standard for detecting small fiber neuropathy, nerve conduction studies are the established diagnostic tool for large fiber involvement. However, several novel and non-invasive diagnostic tools have emerged recently, offering improved screening options for early-stage and subclinical DPN. The frequent presence of asymptomatic neuropathy in pediatric populations, combined with its limited treatment options, underscores the importance of early identification of modifiable risk factors thus reducing the risk of developing clinically significant DPN. This review provides a comprehensive overview of the current evidence on the prevalence, risk factors, and modern diagnostic approaches for DPN in children with diabetes.

**Keywords:** Diabetes type 1, diabetic neuropathy, children

## Introduction

Diabetic peripheral neuropathy (DPN) is a common complication of diabetes and the most common type of acquired neuropathy. Classically, DPN is defined as the presence of symptoms and/or signs of peripheral nerve dysfunction in patients with diabetes after the exclusion of other causes (1). Typically, this is a chronic complication of diabetes but acute cases also occur (2). Sensory, motor, or autonomic nerves may be affected, often coexisting (1). There is no universally accepted classification for DPN. The American Diabetes Association classified diabetic neuropathies into three main categories: 1) diffuse neuropathy (distal

symmetric polyneuropathy and autonomic); 2) mononeuropathy; and 3) radiculopathy or polyradiculopathy (3) (Figure 1). There are two stages of DPN, subclinical and clinical. Subclinical DPN implies neurophysiological changes in nerve function without clinical symptoms. The manifestation of nervous dysfunction characterizes clinical DPN (4).

The most common type of DPN is distal symmetric polyneuropathy (3). It may involve large-fiber nerves (related to touch, vibration, position perception, and muscle control) and small-fiber nerves (affected thermal perception, pain, and

**Corresponding Author:** Marta Baszyńska-Wilk, MD, The Children's Memorial Health Institute, Clinic of Endocrinology and Diabetology, Warsaw, Poland

**E-mail:** m.baszynska-wilk@ipczd.pl **ORCID:** orcid.org/0000-0001-8741-3518

**Conflict of interest:** None declared

**Received:** 10.04.2025 **Accepted:** 14.08.2025 **Epub:** 28.08.2025 **Publication Date:** 13.03.2026






Figure 1. The classification of diabetic neuropathy modified from American Diabetes Association (3)

autonomic function) (Table 1). Most patients, however, have both large- and small-nerve fiber damage. Sensory symptoms include numbness, paresthesia, and neuropathic pain. Symptoms begin in the toes and fingers before progressing in a stocking and then a glove distribution as the disease progresses. In the pediatric population, most patients present with subclinical neuropathy. In the case of clinical manifestation, pain, and dysesthesias are the most common presentations (5).

The US Food and Drug Administration has not approved any casual treatments for DPN. Hence, prevention, reducing risk factors, and finding appropriate screening tests that enable diagnosis at an early stage of the disease are essential (3).

The review aims to summarize the data on the prevalence, diagnostic methods, and risk factors of DPN in children and adolescents, especially in type 1 diabetes (T1D).

### Prevalence of Diabetic Neuropathy

The prevalence of DPN in T1D ranges widely from 3% to 62% (6,7,8). There is a variation between the results of the studies, which are limited and hard to compare due to differences in age ranges, clinical definitions and diagnostic tests for DPN. The data are summarized in Table 2. The Pittsburgh Epidemiology of Diabetes Complications Study revealed diabetic neuropathy in only 3% of patients under 18 years old, 18% for 18- to 29-year-old patients, and 58% for >30-year-old patients (6). The EURODIAB insulin-dependent diabetes mellitus complications study, one

of the largest and most important epidemiological studies on T1D in children and adolescents in Europe, reported diabetic neuropathy in 19% of patients aged 15 to 29 years (9). The Danish Study Group reported subclinical neuropathy in 62% of patients aged 12-27 years, diagnosed by vibration detection threshold (VDT) (10). However, Nelson et al.'s (11) identified neuropathy in 57% of patients using one of the gold standard methods, a nerve conduction study (NCS). The SEARCH for diabetes in youth study (SEARCH) is a multicenter, population-based study designed to assess the incidence, prevalence, and complications of diabetes among children and adolescents in the United States. Data from SEARCH showed that 7% of adolescent patients had evidence of neuropathy, as diagnosed by the Michigan Neuropathy Screening Instrument (MNSI) (12).

### Diagnostic Methods

International Society for Pediatric and Adolescent Diabetes recommends that screening for DPN in young people with T1D should start at puberty or from age 11 years if the child has had diabetes for 2-5 years and screening should be repeated annually (13).

Clinical findings suggestive of DPN include a loss of sensation to pinprick, temperature, vibration, and proprioception (5). Neurological examination should consist of reflex testing because loss of ankle reflexes can occur in the early stage of DPN. Weakness of small foot muscles and dorsiflexion is usually observed later (5).

**Table 1. Diabetic peripheral neuropathy: small fiber vs. large fiber (4,5)**

Nerve type	Fiber class	Nerve function	Fiber myelination	Function	Symptoms of neuropathy
Large-fiber	Aα	Motor	Myelinated	Muscle control	- Impaired vibration sense, - Loss of position sense, - Muscle weakness, - Loss of deep tendon reflexes
	Aα/β	Sensory	Myelinated	Position perception, touch, vibration	
Small-fiber	Aδ	Sensory	Thinly myelinated	Cold, pain (fast and well-localized)	- Pain and paresthesia, - Loss of temperature perception - Normal tendon reflexes, - Autonomic signs and symptoms
	C	Sensory	Unmyelinated	Cold and warmth, pain (slow and poorly localized)	
	C	Autonomic	Unmyelinated	Blood pressure, heart rate, sweating, gastrointestinal and genitourinary system control	

**Table 2. The summary of studies evaluating diabetic neuropathy in children and adolescents**

Study	No. of patients	Diagnostic methods	Prevalence of DPN (age range)
Maser et al. (6) Pittsburgh Epidemiology of Diabetes complications study	400	- Clinical symptoms, - Neurological examination	3% (<18 years)
Tesfaye et al. (9) EURODIAB IDDM	3250	- Clinical symptoms, - Neurological examination, - Vibration perception threshold, - Autonomic dysfunction	19% (15-29 years)
Olsen et al. (10) Danish Study Group	339	- Vibration perception threshold	5% (10-15 years) 46.8% (15-20 years)
Nelson et al. (11)	73	- NCS	57% (mean age 13.7±2.6 years)
Jaiswal et al. (12) SEARCH	1734	- MNSI	7% (mean age 18±4 years)
Moser et al. (8)	151	- MNSI, - NCS (in case of a positive result of MNSI or in a high risk group).	10.6% (8-21 years)

IDDM: insulin-dependent diabetes melitus, NCS: nerve conduction studies, MNSI: Michigan Neuropathy Screening Instrument

## Screening Tests

### Touch Sensation Tests

Touch sensation tests assess the integrity of Merkel touch domes and Meissner corpuscles and their associated large-diameter fibers. The Semmes-Weinstein monofilament test, Neuropen, and the Ipswich touch test can be used to evaluate touch sensation. Frey’s hair test may also allow the examination of touch perception thresholds (14).

There are different types of monofilament, e.g., 0.5 g, 2 g, 10 g, 50 g, and 200 g. A 10 g monofilament test is the most common, in practice. The Neuropen combines an interchangeable 10 g monofilament and a calibrated sterile Neurotip for assessing pain sensation. The Ipswich touch test is a simple method where the tip of an index finger is used to elicit the sensation of light touch on the tips of the patient’s first, third, and fifth toes for 1-2 seconds. Compared with the 10-g monofilament, the Ipswich Touch Test has a sensitivity and specificity of 76% and

90%, respectively, and can be done at home without equipment (7). Frey’s hairs are based on a method similar to that of a monofilament; touch perception thresholds can be assessed by buckling the hair which corresponds to a predefined force determined by the filament’s mechanical properties (nominal force of 0.026-110 g) with a force ranging from 0.026 g to 110 g (15).

### Thermal Perception Testing

Thermal perception testing determines the function of free-nerve endings and their associated unmyelinated and thinly myelinated fibers. It is more valuable to test cold and warm perceptions separately. Only thermal threshold testing is capable of assessing small fiber dysfunction (5,14,16).

One of the simple screening methods for testing thermal perception is tip-therm. It is an instrument with two flat sides of a special polymer and a metal alloy. Due to the different thermal conductivity of both materials, the faces of the instruments are

perceived differently. Compared to the biothesiometer, tip-therm has high specificity (100%) and sensitivity (97.3%) in diagnosing diabetic neuropathy (16).

### Vibratory Sensation Test

Vibration perception testing assesses function in the Meissner, and Pacinian corpuscles, and large-diameter fibers. Typical testing sites are the glabrous skin of the fingers and toes (5,14,17). For the vibration perception assessment, a 128-Hz standard tuning fork, vibra tip, Rydel-Seiffer fork, or biothesiometer are used (5).

A 128-Hz standard tuning fork determines the presence or absence of vibration perception. There are two methods of examination: on-off and timing method. In the first method, a tuning fork is applied to the bony prominence bilaterally situated at the dorsum of the first toe. The patient reports the start and the cessation of the vibration sensation. In the timing method, a tuning fork is applied to the same area, and the patient reports the time at which vibration diminished beyond perception. The results compare to the examiner's timing of vibration sensation (17).

There is also a pocket-size device, the VibraTip, for assessing vibration perception in DPN screening. It provides a stimulus of 128 Hz (5).

Quantitative methods, including the Rydel-Seiffer tuning fork (RSTF) and the biothesiometer (5), have been developed to determine VDT. The RSTF allows the testing of various vibration intensities by the patient to assess vibratory discrimination. A triangle and a scale from 0 to 8 imprinted on the weights allow assessment of the vibration threshold (18). After the tuning fork is struck to initiate vibration, its base is applied to a bony prominence. The patient is asked to indicate when the vibration sensation disappears, at which point the examiner records the corresponding value on the triangular scale displayed on the prongs of the tuning fork. Scores range from 8, indicating normal vibration perception, through 5-7 (mild reduction) and 3-4 (moderate impairment), to 0-2, reflecting severe sensory loss or complete absence of vibration perception (19).

The biothesiometer determines VDT on a scale from 0 to 50. It measures VDT by adjusting the amplitude of an electrical vibrator. In contrast to the RSTF, a biothesiometer measures the VDT as the point at which the first sensation of the vibration appears (20). Assessment of VDT using a biothesiometer is quick and reliable. Compared with a tuning fork, the biothesiometer has been reported to be more accurate (21).

### New Quantitative Sensory Test

A quantitative sensory test (QST) determines the sensory threshold, which is defined as the minimal energy detected for a

particular modality. Using direct patient feedback, QST measures sensory thresholds, such as vibration, cold, warmth, heat, or cold pain. There are two schemes: the method of limits and the method of levels. In the method of limits, a patient indicates as soon as an increasingly strong stimulus is detected or when a decreasing stimulus is no longer felt. In the method of levels, stimuli of defined intensity levels are tested, and the patient is asked to indicate if the stimulus is or is not detected. In the method of limits, the result is dependent on the rate of change of the stimuli and is more variable than the method of levels and will also be affected by a patient's reaction time (22).

### Scoring System

Various clinical scoring systems are used to screen DPNs. They may involve symptom scoring, sign scoring, or both (Table 3) (23,24,25,26,27,28,29,30). The scoring system is a suitable and easy-to-perform method for the early detection of DPN. The MNSI is a widely used screening tool, including in the pediatric population. However, it has not been formally validated in children. Research in the adult population has shown a range of sensitivity (35-79%) and specificity (65-94%) compared to NCS, depending on the cut-off value used for abnormality in MNSI (23).

### Gold Standard

#### Skin Biopsy

A skin biopsy is a relatively minimally invasive technique and the specimen is taken from the distal calf. Assessing intraepidermal nerve fibers (IENF) counts, lengths, and densities is key when identifying small fiber neuropathy (SFN). IENFs are the last endings of C and A-delta fibers, participating in pain perception and detection of thermal stimuli (31). There are two evaluation methods for IENFs: immunohistochemical (bright-field) or indirect immunofluorescence with and without confocal analysis. Nerve fiber staining is performed with protein gene product 9.5 (PGP9.5), a member of the ubiquitin hydroxylase system, and PGP9.5 is a non-specific pan-neuronal marker (31,32).

In clinical practice, IENF density (IENFD) is the gold standard for diagnosing conditions with small nerve fiber involvement. Diabetes is the most common cause of SFN, and a decrease in IENFD may be evident in the earliest stage of the disease. Moreover, IENFD can be used to monitor the progression of diabetic SFN, and a decrease in IENFD correlates with the severity of SFN (32).

Mechanoreceptors, innervated by A-beta fiber endings, can also be identified in skin biopsy samples. NCS is a gold standard for diagnosing large fiber neuropathy (LFN). However, skin biopsy allows assessment of early abnormalities of receptors and the distal part of myelinated fibers.

Table 3. Clinical scoring for DPN screening		
Test	Description	Score
<b>Signs and symptoms</b>		
Michigan Neuropathy Screening Instrument (MNSI) (23,24)	Consist of 15 questions completed by patient, and physical assessment: appearance of feet, ulceration, ankle reflex, vibration perception at great toe, monofilament testing.	≥7/15 positive results of the questionnaire; ≥2/8 positive results of physical examination.
Toronto clinical neuropathy score (TCNS) (25)	Three items: symptoms (pain, numbness, tingling, weakness, ataxia, upper -limb symptoms), reflex (knee and ankle reflexes) and sensory test score (pinprick, temperature, light touch, vibration sense, position sense).	0-5 points without DPN; 6-8 points mild DPN; 9-11 points moderate DPN; 12 to 19 points severe DPN.
The Douleur Neuropathique en 4 (DN4) (26)	Includes questions for different types of neuropathic pain and a physical exam to test for touch and pin hypoesthesia and tactile dynamic allodynia.	≥4/10 positive result. Available pediatric version
<b>Symptoms</b>		
Neuropathy symptoms score (NSS) (27)	Seventeen items, symptoms of muscle weakness, sensory disturbances, autonomic symptoms .	≥1/17 positive result.
Diabetic neuropathy symptoms score (DNS) (28)	Four questions, simplified scoring system, assessing pain, numbness, tingling and ataxia.	≥1/4 positive result.
<b>Signs</b>		
Neuropathy disability score (NDS) (29)	Thirty-five items evaluating cranial nerve, sensation, reflexes, muscle strength. Revised NDS: ankle reflex, vibration, pinprick and temperature sensation at both sides of the largest toes.	≥2/10 positive result.
Diabetic neuropathy examination (DNE) (30)	Tree items: muscle strength (quadriceps femoris - extension of the knee; tibialis anterior - dorsiflexion of the foot), reflex (triceps surae), sensation index finger (pinprick) and big toe (pinprick, touch, vibration sensation, sensitivity to joint position).	>3/16 positive result.
DPN: diabetic peripheral neuropathy		

Autonomic involvement can also be assessed through skin biopsy. In DPN, a significant loss of sudomotor (innervating the sweat glands) and pilomotor (controlling erector pili muscle contraction leading to hair follicle erection) nerve fibers has been demonstrated (32).

## NCS

NCS is the gold standard for the diagnosis of LFN (5). The Toronto consensus for a firm diagnosis of LFN requires at least one symptom and/or at least one sign of neuropathy and abnormality on NCS (33). During the examination, small pads are inserted into the skin, deliver mild electric shocks, and detect electric signals. Routine NCS includes evaluation of the motor function of the median, ulnar, peroneal, and tibial nerves and the sensory function of the median, ulnar, radial, and sural nerves. Recommended attributes are amplitude, distal latency, distance, conduction velocity, and F-wave latency. Diagnostic criteria involve the abnormality of one or more attributes in two or more separate nerves to diagnose DPN (34). NCS may not be widely available for routine diagnostic evaluation of DPN. Furthermore, NCS is insensitive for the diagnosis of SFN (35).

## Other Methods

### Neuropad

A simple indicator test that can detect the early stage of peripheral neuropathy is Neuropad. The Neuropad is applied to the plantar aspect of the first metatarsal head and removed after 10 minutes. It assesses sweat production by the color change of a cobalt II compound from blue to pink. Color change indicates sudomotor dysfunction in DPN, which usually develops before sensory loss. The sensitivity of the test was reported to be 70-83% when validated against the Neuropathy Disability Score, NCS, and VDT (36).

### Sudoscan

Sudoscan is a non-invasive, quantitative test to assess sudomotor function using reverse iontophoresis to measure electrochemical skin conductance (ESC) of sweat in the hands and feet. It evaluates the function of small C-fibers that innervate the sweat glands. Degeneration of these fibers results in reduced sweat gland function (37). Validation studies have confirmed good values for sensitivity (70-87.5%) when using foot ESC results to screen

for DPN (38). Global collaborative analysis established reference values in healthy subjects for different ethnic groups, ages, and by gender (39).

### Corneal Confocal Microscopy

Corneal confocal microscopy (CCM) is a relatively new, non-invasive diagnostic tool for SFN. Nerve fibers from the trigeminal richly innervate the cornea. Corneal nerve fiber density, corneal nerve branch density, corneal nerve fiber length, and inferior whorl length are the main parameters used. A meta-analysis of over 3,000 participants revealed a reduction in the CCM parameter in patients with DPN compared with healthy controls and those without DPN. In addition, the authors also reported a lesser, but significant, decrease in CCM parameters in diabetic patients without DPN compared with controls, suggesting that CCM may identify subclinical DPN (40). Corneal nerve loss was also observed in patients with only impaired glucose tolerance (41) and in children with T1D (42).

### Optical Coherence Tomography Angiography

Optical coherence tomography angiography (OCTA) is a non-invasive tool that enables quantitative assessment of retinal microcirculation. Research highlights the value of OCTA in monitoring neurodegeneration in patients with T1D. The potential of OCTA as an imaging biomarker for evaluating the progression of DPN has been suggested (43).

### Risk Factors

Diabetic neuropathy develops as a result of various risk factors, which can be categorized into modifiable and non-modifiable. Identifying and assessing these factors is essential for preventing DPN.

Non-modifiable factors include disease duration, pubertal status, tall stature, ethnicity, and genetic predisposition. Modifiable factors include glycemic control, dyslipidemia, and hypertension.

## Non-modifiable Factors

### Duration of Diabetes

Long-standing diabetes is a confirmed risk factor for DPN. In SEARCH, in patients with DPN, diabetes duration was significantly longer, but HbA1C values were similar between groups, indicating that longer diabetes duration regardless of metabolic control is a crucial factor in DPN (12).

### Tall Stature

In contrast to nephropathy and retinopathy (complications of diabetes, which more often occur in patients with short stature), tall stature was associated with a higher prevalence of

neuropathy. Some hypotheses exist, such as patients with longer nerves (and thus a larger total axon surface area) who may be at greater risk for neurologic impairment and have a prolonged time requirement for complete regeneration. The association of height with peripheral neuropathy might be related to the increased hydrostatic pressure in tall patients during standing upright (44).

### Puberty

Research has shown that puberty contributes to the development of late metabolic complications of diabetes, such as retinopathy and neuropathy (45). Peripheral nerve function is increasingly impaired during puberty. A cross-sectional study demonstrated an increasing subclinical motor nerve impairment detected during late puberty and after puberty. Reduced sensory nerve conduction velocity (NCV) and sensory nerve action potential amplitude were confirmed. The peripheral nerve fibers of pubertal and postpubertal patients may be the most vulnerable to nerve demyelination and axonal damage caused by poor metabolic control induced by pubertal hormonal changes and poor self-care during puberty (46).

### Ethnicity

The prevalence of DPN varies according to ethnicity. Studies of multi-ethnic groups have found a greater prevalence of DPN occurring in Caucasian patients compared to other ethnic groups (47).

### Genetic Markers

There are limited data on genetic predisposition to DPN among children with T1D. Single nucleotide polymorphism is a variation at a single position in the DNA sequence among individuals, which can be linked to a higher or lower risk of diseases. A Slovak study confirmed a strong association between the Cytochrome b-245 alpha chain (CYBA) polymorphism *rs4673* and DPN in children and adolescents with T1D. *CYBA* encodes the p22<sup>phox</sup> protein, a subunit of the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase complex, which plays a key role in the production of reactive oxygen species (48).

A study by Stokov et al. (49) reported that the polymorphic markers Ala(-9)Val in the *Superoxide Dismutase 2 (SOD2)* gene and Arg213Gly in the *SOD3* gene were associated with a higher risk of DPN. *SOD2* and *SOD3* encode different isoforms of the enzyme SOD, which plays a key role in protecting cells from oxidative stress (49).

Vascular endothelial growth factor (VEGF) is a signaling protein that plays a critical role in angiogenesis. However, it has been reported that the distribution of a *VEGF* gene polymorphism in the promoter region (-7C/T) differed significantly between

patients with T1D with and without neuropathy, and may be implicated in the pathogenesis of DPN (50).

## Modifiable Factors

### Hyperglycemia

Hyperglycemia is a well-known risk factor for DPN. A study in children and youth with T1D confirmed an elevated DPN risk with poor glycemic control. EURODIAB determined the association of DPN with the duration of diabetes and highlights a strong relation with glycemic control independent of diabetes duration (9).

### Glycemic Variability

In addition to hyperglycemia, glycemic variability (GV) may be another independent risk factor for diabetic complications, but results are inconsistent. Some studies propose potential pathophysiological mechanisms through which elevated GV contributes to the development of DPN. These include the activation of protein kinase C-dependent NADPH oxidase, which subsequently induces oxidative stress. Furthermore, an oxidative stress and inflammatory response is caused by activating the nuclear factor kappa-light-chain-enhancer of activated B cells pathway (51,52).

The study by Oberhauser et al. (53), conducted among children and adolescents with T1D, confirmed that high GV was an unexpectedly strong predictor of slowed NCV. However, there are limited studies on the long-term outcomes of GV during the pediatric period, so further prospective research is needed (54).

### Obesity

Obesity is an emerging risk factor for neuropathy, independent of hyperglycemia. Obesity may contribute to the development of neuropathy through several mechanisms, including oxidative stress, insulin resistance, metabolic inflammation, and ischemia, all of which can lead to nerve degeneration (55). Fat distribution is likely more important than general obesity in developing neuropathy. Among adolescents with obesity, the association of central adiposity with insulin resistance and inflammation has been confirmed. This effect is observed regardless of body mass index (56). Visceral adipose tissue is a source of pro-inflammatory mediators, including cytokines such as tumor necrosis factor- $\alpha$  and interleukin-6, and is associated with elevated levels of the acute-phase reactant C-reactive protein. These cytokines activate microglia and perivascular macrophages, ultimately promoting demyelination and axonal degeneration. Moreover, an excess of free fatty acids, particularly in central obesity, may cause direct damage to neural structures (57). Studies in childhood cohorts reveal a correlation between obesity and increased risk for neuropathy (58).

### Dyslipidemia

Dyslipidemia increases the frequency and severity of micro- and macro-vascular complications in T1D. Large clinical studies like EURODIAB and SEARCH have confirmed the relationship between lipid disturbances and peripheral neuropathy. In EURODIAB, higher levels of total and low-density lipoprotein cholesterol (LDL-c) and triglycerides were significantly associated with the cumulative incidence of neuropathy (9). SEARCH found increased triglycerides, LDL-c, and lower levels of high-density lipoprotein cholesterol (HDL-c) as a risk factor for DPN in youth with T1D. The authors suggested that the lower HDL-c could be one of the crucial factors in the pathogenesis of DPN. HDL-c inhibits inflammation process, oxidation, and thrombosis, as well as vasodilatation via endothelial release of nitric oxide. Increasing HDL-c levels through lifestyle modification (dietary modification, aerobic exercise, weight loss) may be one of the therapeutic approaches (12).

### Hypertension

Studies confirmed that hypertension was associated with the prevalence of neuropathy in young people with T1D (59). Hypertension is associated with impaired nerve conduction in T1D (60). Glycemic control has to be supported with strict blood pressure control to prevent and delay the onset of DPN. According to EURODIAB the risk factors for DPN in youth with T1D are increased diastolic blood pressure (9). The angiotensin-converting enzyme inhibitor (ACEI) may improve peripheral neuropathy even in normotensive patients with diabetes (61). Hyperglycemia increases tissue angiotensin II, causing oxidative stress, endothelial damage, and vascular changes. These contribute to DPN and can be diminished by blocking the renin-angiotensin system, which may explain the beneficial effect of therapy with ACEIs (62).

## Conclusion

DPN is one of the most common complications of diabetes, which can result in foot ulcers and potentially necessitate amputation. The prevalence of neuropathy in patients with T1D differs, based on the screening methods used and the characteristics of the study groups. Nevertheless, the studies reviewed indicate a relatively high occurrence of subclinical neuropathy, highlighting the need for early detection of risk factors to prevent this complication. Of note, therapeutic options are currently very limited, so early screening and modification of risk factors is very important in patients with T1D.

## Footnotes

### Authorship Contributions

Concept: Marta Baszyńska-Wilk, Monika Nowacka-Gotowiec, Elżbieta Moszczyńska, Design: Marta Baszyńska-Wilk, Data Collection and Processing: Marta Baszyńska-Wilk, Monika Nowacka-Gotowiec, Analysis and Interpretation: Marta Baszyńska-Wilk, Monika Nowacka-Gotowiec, Elżbieta Moszczyńska, Literature Research: Marta Baszyńska-Wilk, Writing: Marta Baszyńska-Wilk, Elżbieta Moszczyńska.

**Financial Disclosure:** The authors declared that this study received no financial support.

## References

1. Boulton AJ, Gries FA, Jervell JA. Guidelines for the diagnosis and outpatient management of diabetic peripheral neuropathy. *Diabet Med*. 1998;15:508-514.
2. Baszyńska-Wilk M, Wysocka-Mincewicz M, Świercz A, Świdarska J, Marszał M, Szalecki M. Peripheral neuropathy as a complication of diabetic ketoacidosis in a child with newly diagnosed diabetes type 1: a case report. *J Clin Res Pediatr Endocrinol*. 2018;10:289-293. Epub 2017 Dec 8
3. Pop-Busui R, Boulton AJ, Feldman EL, Bril V, Freeman R, Malik RA, Sosenko JM, Ziegler D. Diabetic neuropathy: a position statement by the American Diabetes Association. *Diabetes Care*. 2017;40:136-154.
4. Anandhanarayanan A, Teh K, Goonoo M, Tesfaye S, Selvarajah D. Diabetic neuropathies. 2022 Mar 15. In: Feingold KR, Adler RA, Ahmed SF, Anawalt B, Blackman MR, Chrousos G, Corpas E, de Herder WW, Dhatriya K, Dungan K, Hamilton E, Hofland J, Jan de Beur S, Kalra S, Kaltsas G, Kapoor N, Kim M, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Sperling MA, Stratakis CA, Trencle DL, Wilson DP, editors. *Endotext* [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000.
5. Akinci G, Savellieff MG, Gallagher G, Callaghan BC, Feldman EL. Diabetic neuropathy in children and youth: new and emerging risk factors. *Pediatr Diabetes*. 2021;22:132-147. Epub 2020 Nov 24
6. Maser RE, Steenkiste AR, Dorman JS, Nielsen VK, Bass EB, Manjoo Q, Drash AL, Becker DJ, Kuller LH, Greene DA, et al. Epidemiological correlates of diabetic neuropathy. Report from Pittsburgh epidemiology of diabetes complications study. *Diabetes*. 1989;38:1456-1461.
7. Franceschi R, Mozzillo E, Di Candia F, Rosanio FM, Leonardi L, Liguori A, Micheli F, Cauvin V, Franzese A, Piona CA, Marcovecchio ML. A systematic review of the prevalence, risk factors and screening tools for autonomic and diabetic peripheral neuropathy in children, adolescents and young adults with type 1 diabetes. *Acta Diabetol*. 2022;59:293-308. Epub 2022 Jan 28
8. Moser JT, Langdon DR, Finkel RS, Ratcliffe SJ, Foley LR, Andrews-Rearson ML, Murphy KM, Lipman TH. The evaluation of peripheral neuropathy in youth with type 1 diabetes. *Diabetes Res Clin Pract*. 2013;100:e3-e6. Epub 2013 Feb 5
9. Tesfaye S, Stevens LK, Stephenson JM, Fuller JH, Plater M, Ionescu-Tirgoviste C, Nuber A, Pozza G, Ward JD. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM complications study. *Diabetologia*. 1996;39:1377-1384.
10. Olsen BS, Johannesen J, Sjølie AK, Borch-Johnsen K, Hougaard P, Thorsteinsson B, Pramming S, Marinelli K, Mortensen HB. Metabolic control and prevalence of microvascular complications in young Danish patients with type 1 diabetes mellitus. Danish Study Group of Diabetes in Childhood. *Diabet Med*. 1999;16:79-85.
11. Nelson D, Mah JK, Adams C, Hui S, Crawford S, Darwish H, Stephure D, Pacaud D. Comparison of conventional and non-invasive techniques for the early identification of diabetic neuropathy in children and adolescents with type 1 diabetes. *Pediatr Diabetes*. 2006;7:305-310.
12. Jaiswal M, Divers J, Dabelea D, Isom S, Bell RA, Martin CL, Pettitt DJ, Saydah S, Pihoker C, Standiford DA, Dolan LM, Marcovina S, Linder B, Liese AD, Pop-Busui R, Feldman EL. Prevalence of and risk factors for diabetic peripheral neuropathy in youth with type 1 and type 2 diabetes: SEARCH for diabetes in youth study. *Diabetes Care*. 2017;40:1226-1232. Epub 2017 Jul 3
13. Bjornstad P, Dart A, Donaghue KC, Dost A, Feldman EL, Tan GS, Wadwa RP, Zabeen B, Marcovecchio ML. ISPAD Clinical Practice Consensus Guidelines 2022: microvascular and macrovascular complications in children and adolescents with diabetes. *Pediatr Diabetes*. 2022;23:1432-1450.
14. Alsunousi S, Marrif HI. Diabetic neuropathy and the sensory apparatus "meissner corpuscle and merkel cells". *Front Neuroanat*. 2014;8:79.
15. Moharić M, Vidmar G, Burger H. Sensitivity and specificity of von Frey's hairs for the diagnosis of peripheral neuropathy in patients with type 2 diabetes mellitus. *J Diabetes Complications*. 2012;26:319-322. Epub 2012 Jun 12
16. Viswanathan V, Snehalatha C, Seenar R, Ramachandran A. Early recognition of diabetic neuropathy: evaluation of a simple outpatient procedure using thermal perception. *Postgrad Med J*. 2002;78:541-542.
17. Perkins BA, Olaleye D, Zinman B, Bril V. Simple screening tests for peripheral neuropathy in the diabetes clinic. *Diabetes Care*. 2001;24:250-256.
18. Martina IS, van Koningsveld R, Schmitz PI, van der Meché FG, van Doorn PA. Measuring vibration threshold with a graduated tuning fork in normal aging and in patients with polyneuropathy. European Inflammatory Neuropathy Cause and Treatment (INCAT) Group. *J Neurol Neurosurg Psychiatry*. 1998;65:743-747.
19. Liniger C, Albeanu A, Assal JP. Measuring diabetic neuropathy. "Low tech" vs. "high tech." *Diabetes Care*. 1990;13:180-181.
20. Bloom S, Till S, Sönksen P, Smith S. Use of a biothesiometer to measure individual vibration thresholds and their variation in 519 non-diabetic subjects. *Br Med J (Clin Res Ed)*. 1984;288:1793-1795.
21. Temlett JA. An assessment of vibration threshold using a biothesiometer compared to a C128-Hz tuning fork. *J Clin Neurosci*. 2009;16:1435-1438.
22. Shy ME, Frohman EM, So YT, Arezzo JC, Cornblath DR, Giuliani MJ, Kincaid JC, Ochoa JL, Parry GJ, Weimer LH; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Quantitative sensory testing: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology*. 2003;60:898-904.
23. Moghtaderi A, Bakhshpour A, Rashidi H. Validation of Michigan neuropathy screening instrument for diabetic peripheral neuropathy. *Clin Neurol Neurosurg*. 2006;108:477-481. Epub 2005 Sep 16
24. Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. *Diabetes Care*. 1994;17:1281-1289.
25. Bril V, Perkins BA. Validation of the Toronto Clinical Scoring System for diabetic polyneuropathy. *Diabetes Care*. 2002;25:2048-2052.
26. Spallone V, Morganti R, D'Amato C, Greco C, Cacciotti L, Marfia GA. Validation of DN4 as a screening tool for neuropathic pain in painful diabetic polyneuropathy. *Diabet Med*. 2012;29:578-585.
27. Dyck PJ, Karnes J, O'Brien PC, Swanson CJ. Neuropathy symptom profile in health, motor neuron disease, diabetic neuropathy, and amyloidosis. *Neurology*. 1986;36:1300-1308.
28. Meijer JW, van Sonderen E, Blaauwwekel EE, Smit AJ, Groothoff JW, Eisma WH, Links TP. Diabetic neuropathy examination: a hierarchical scoring system to diagnose distal polyneuropathy in diabetes. *Diabetes Care*. 2000;23:750-753.

29. Weintrob N, Amitay I, Lilos P, Shalitin S, Lazar L, Josefsberg Z. Bedside neuropathy disability score compared to quantitative sensory testing for measurement of diabetic neuropathy in children, adolescents, and young adults with type 1 diabetes. *J Diabetes Complications*. 2007;21:13-19.
30. Meijer JWG, Bosma E, Lefrandt JD, Links TP, Smit A, Stewart R, Hoaven JH, Hoogenberg K. Clinical diagnosis of diabetic polyneuropathy with the diabetic neuropathy symptom and diabetic neuropathy examination scores. *Diabetes Care*. 2003;26:697-701.
31. Nolano M, Tozza S, Caporaso G, Provitera V. Contribution of skin biopsy in peripheral neuropathies. *Brain Sci*. 2020;10:989.
32. Nebuchennykh M, Løseth S, Lindal S, Mellgren SI. The value of skin biopsy with recording of intraepidermal nerve fiber density and quantitative sensory testing in the assessment of small fiber involvement in patients with different causes of polyneuropathy. *J Neurol*. 2009;256:1067-1075. Epub 2009 Mar 1
33. Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, Lauria G, Malik RA, Spallone V, Vinik A, Bernardi L, Valensi P; Toronto Diabetic Neuropathy Expert Group. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. *Diabetes Care*. 2010;33:2285-2293.
34. Dyck PJ, Carter RE, Litchy WJ. Modeling nerve conduction criteria for diagnosis of diabetic polyneuropathy. *Muscle Nerve*. 2011;44:340-345.
35. Perkins BA, Ngo M, Bril V. Symmetry of nerve conduction studies in different stages of diabetic polyneuropathy. *Muscle Nerve*. 2002;25:212-217.
36. Ponirakis G, Petropoulos IN, Fadavi H, Alam U, Asghar O, Marshall A, Tavakoli M, Malik RA. The diagnostic accuracy of neuropad for assessing large and small fibre diabetic neuropathy. *Diabet Med*. 2014;31:1673-1680. 12536. Epub 2014 Jul 14
37. Gin H, Baudoin R, Raffaitin CH, Rigalleau V, Gonzalez C. Non-invasive and quantitative assessment of sudomotor function for peripheral diabetic neuropathy evaluation. *Diabetes Metab*. 2011;37:527-532. Epub 2011 Jun 28
38. Casellini CM, Parson HK, Richardson MS, Nevoret ML, Vinik AI. Sudoscan, a noninvasive tool for detecting diabetic small fiber neuropathy and autonomic dysfunction. *Diabetes Technol Ther*. 2013;15:948-953. Epub 2013 Jul 27
39. Vinik AI, Smith AG, Singleton JR, Callaghan B, Freedman BI, Tuomilehto J, Bordier L, Bauduceau B, Roche F. Normative values for electrochemical skin conductances and impact of ethnicity on quantitative assessment of sudomotor function. *Diabetes Technol Ther*. 2016;18:391-398. Epub 2016 Apr 8
40. Gad H, Petropoulos IN, Khan A, Ponirakis G, MacDonald R, Alam U, Malik RA. Corneal confocal microscopy for the diagnosis of diabetic peripheral neuropathy: a systematic review and meta-analysis. *J Diabetes Investig*. 2022;13:134-147. Epub 2021 Aug 27
41. Asghar O, Petropoulos IN, Alam U, Jones W, Jeziorska M, Marshall A, Ponirakis G, Fadavi H, Boulton AJ, Tavakoli M, Malik RA. Corneal confocal microscopy detects neuropathy in subjects with impaired glucose tolerance. *Diabetes Care*. 2014;37:2643-2646. Epub 2014 Jun 26
42. Ferdousi M, Romanchuk K, Mah JK, Virtanen H, Millar C, Malik RA, Pacaud D. Early corneal nerve fibre damage and increased Langerhans cell density in children with type 1 diabetes mellitus. *Sci Rep*. 2019;9:8758.
43. Wysocka-Mincewicz M, Gołębiewska J, Baszyńska-Wilk M, Olechowski A, Byczyńska A, Mazur M, Nowacka-Gotowiec M. Associations of nerve conduction parameters and OCT angiography results in adolescents with type 1 diabetes. *PLoS One*. 2021;16:e0252588.
44. Wadén J, Forsblom C, Thorn LM, Saraheimo M, Rosengård-Bärlund M, Heikkilä O, Hietala K, Ong K, Wareham N, Groop PH; FinnDiane Study Group. Adult stature and diabetes complications in patients with type 1 diabetes: the FinnDiane study and the diabetes control and complications trial. *Diabetes*. 2009;58:1914-1920. Epub 2009 Jun 2
45. Wysocka-Mincewicz M, Gołębiewska J, Baszyńska-Wilk M, Olechowski A, Byczyńska A, Szałecki M. Influence of puberty on retinal microcirculation in children with type 1 diabetes without retinopathy using optical coherence tomography angiography. *Diab Vasc Dis Res*. 2021;18:14791641211004427.
46. Riihimaa PH, Suominen K, Tolonen U, Jäntti V, Knip M, Tapanainen P. Peripheral nerve function is increasingly impaired during puberty in adolescents with type 1 diabetes. *Diabetes Care*. 2001;24:1087-1092.
47. Sosenko JM. The prevalence of diabetic neuropathy according to ethnicity. *Curr Diab Rep*. 2009;9:435-439.
48. Snahnicanova Z, Mendelova A, Grendar M, Holubekova V, Kostkova M, Pozorciakova K, Jancinová M, Kasubova I, Vojtkova J, Durdik P, Lasabova Z, Ciljakova M, Banovcin P. Association of polymorphisms in CYBA, SOD1, and CAT genes with type 1 diabetes and diabetic peripheral neuropathy in children and adolescents. *Genet Test Mol Biomarkers*. 2018;22:413-419. Epub 2018 Jun 20
49. Stokov IA, Bursa TR, Drepa OI, Zotova EV, Nosikov VV, Ametov AS. Predisposing genetic factors for diabetic polyneuropathy in patients with type 1 diabetes: a population-based case-control study. *Acta Diabetol*. 2003;40(Suppl 2):S375-S379.
50. Tavakkoly-Bazzaz J, Amoli MM, Pravica V, Chandrasecaran R, Boulton AJ, Larijani B, Hutchinson IV. VEGF gene polymorphism association with diabetic neuropathy. *Mol Biol Rep*. 2010;37:3625-3630. Epub 2010 Mar 30.
51. Quagliaro L, Piconi L, Assaloni R, Martinelli L, Motz E, Ceriello A. Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P) H-oxidase activation. *Diabetes*. 2003;52:2795-2804.
52. Zhang X, Yang X, Sun B, Zhu C. Perspectives of glycemic variability in diabetic neuropathy: a comprehensive review. *Commun Biol*. 2021;4:1366.
53. Oberhauser SS, l'Allemand D, Willems EP, Gozzi T, Heldt K, Eilers M, Stasinaki A, Lütsch J, Broser PJ. Slowing of peripheral nerve conduction velocity in children and adolescents with type 1 diabetes is predicted by glucose fluctuations. *Diabetes*. 2023;72:1835-1840.
54. Bombaci B, Passanisi S, Lombardo F, Salzano G. Clinical relevance of short-term glycemic variability in children and adolescents with type 1 diabetes: a narrative review. *Transl Pediatr*. 2024;13:1231-1241. Epub 2024 Jul 16
55. Hanewinkel R, Drenthen J, Ligthart S, Dehghan A, Franco OH, Hofman A, Ikram MA, van Doorn PA. Metabolic syndrome is related to polyneuropathy and impaired peripheral nerve function: a prospective population-based cohort study. *J Neurol Neurosurg Psychiatry*. 2016;87:1336-1342. Epub 2016 Sep 21
56. Vajravelu ME, Kindler JM, Zemel BS, Jawad A, Koren D, Brar P, Brooks LJ, Reiner J, Levitt Katz LE. Visceral adiposity is related to insulin sensitivity and inflammation in adolescents with obesity and mild sleep disordered breathing. *J Pediatr Endocrinol Metab*. 2022;35:1069-1077.
57. O'Brien PD, Hinder LM, Callaghan BC, Feldman EL. Neurological consequences of obesity. *Lancet Neurol*. 2017;16:465-477.
58. Callaghan BC, Reynolds E, Banerjee M, Chant E, Villegas-Umana E, Feldman EL. Central obesity is associated with neuropathy in the severely obese. *Mayo Clin Proc*. 2020;95:1342-1353.
59. Forrest KY, Maser RE, Pambianco G, Becker DJ, Orchard TJ. Hypertension as a risk factor for diabetic neuropathy: a prospective study. *Diabetes*. 1997;46:665-670.
60. Ponirakis G, Petropoulos IN, Alam U, Ferdousi M, Asghar O, Marshall A, Azmi S, Jeziorska M, Mahfoud ZR, Boulton AJM, Efron N, Nukada H, Malik RA. Hypertension contributes to neuropathy in patients with type 1 diabetes. *Am J Hypertens*. 2019;32:796-803.

61. Malik RA, Williamson S, Abbott C, Carrington AL, Iqbal J, Schady W, Boulton AJ. Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. *Lancet*. 1998;352:1978-1981.
62. Sethi Y, Uniyal N, Vora V, Agarwal P, Murlu H, Joshi A, Patel N, Chopra H, Hasabo EA, Kaka N. Hypertension the 'missed modifiable risk factor' for diabetic neuropathy: a systematic review. *Curr Probl Cardiol*. 2023;48:101581. Epub 2022 Dec 28